Highlights key accomplishments and outlines value drivers for 2017

 

SAN DIEGO, Feb. 9, 2017 -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W. Nall has issued the following letter to stockholders:

 

To Our Stockholders and Friends:

The entire team at Biocept looks forward to 2017, as we work to advance our position as a commercial leader in liquid biopsy.  The past year was eventful as we introduced new high-value biomarker assays, signed in-network provider agreements with major health plans, and reported positive clinical study results that further validate our Target Selector™ platform.  It was gratifying to see these accomplishments reflected in our improved operational and financial performance, with strong year-over-year growth in sample volumes and the achievement of our first million-dollar quarter in the third quarter of 2016. 

Management expects additional positive upcoming results from its trial in healthy volunteers

 

TEL AVIV, Israel, Feb. 08, 2017 -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of stem cells selection technology, today announces that it has treated the first blood cancer patient in the recently initiated Phase I/II trial of its stem cell technology ApoGraft™.

 

The trial is intended to assess the Cellect ApoGraft™ process which is designed to prevent Graft-versus-Host Disease (GvHD), a common complication associated with stem cell transplant in which the transplanted immune cells attack the recipient's body cells and organs. GvHD is a life-threatening condition occurring in up to 50% of stem cell transplants. In this trial, the company will be testing stem cells transplanted from a matched donor related to the patient.

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 4, 2017) - Pyng Medical Corp. (the "Company" or "Pyng") (TSX VENTURE:PYT) is pleased to announce that the Company has entered into a definitive agreement (the "Arrangement Agreement") with Teleflex Incorporated ("Teleflex") and Teleflex Medical Canada Inc. ("Teleflex Medical"), a wholly-owned indirect subsidiary of Teleflex, pursuant to which Teleflex has agreed to cause Teleflex Medical to acquire all of the issued and outstanding common shares of Pyng (the "Shares") for cash consideration of USD $0.30203 per Share (the "Consideration") by way of a court approved plan of arrangement (the "Plan of Arrangement") under the Business Corporations Act (British Columbia) (the "Arrangement"). The Consideration represents a 401% premium to the CAD $0.07868 volume-weighted average trading price of the Shares on the TSX Venture Exchange ("TSX-V") for the 20 trading days ending on February 3, 2017 based on an exchange rate of CAD $1.3047 per USD $1.00, and a 393% premium to the closing price of the Shares on the TSX-V of CAD $0.08 on February 3, 2017. 

University Health Network (UHN) in Toronto to Launch Triple-Combination Study Evaluating the Potential for Enhanced Anti-Cancer Activity of Currently Marketed Checkpoint Inhibitor When Combined With DPX-Survivac

 

HALIFAX, NOVA SCOTIA--(Feb. 6, 2017) - Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that the UHN's Princess Margaret Cancer Centre (PM) will conduct a Phase 2 clinical trial to evaluate the use of a combination of immunotherapies from Immunovaccine and Merck (known as MSD outside the United States and Canada).